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Objectives. To investigate the mechanisms by which bezafibrate
retarded the progression of coronary lesions in the Bezafibrate
Coronary Atherosclerosis Intervention Trial (BECAIT), we exam-
ined the relationships of on-trial lipoproteins and lipoprotein
subfractions to the angiographic outcome measurements.
Background. BECAIT, the first double-blind, placebo-
controlled, randomized serial angiographic trial of a fibrate
compound, showed that progression of focal coronary atheroscle-
rosis in young survivors of myocardial infarction could be re-
tarded by bezafibrate treatment.
Methods. A total of 92 dyslipoproteinemic men who had sur-
vived a first myocardial infarction before the age of 45 years were
randomly assigned to treatment for 5 years with bezafibrate
(200 mg three times daily) or placebo; 81 patients underwent
baseline and at least one post-treatment coronary angiography.
Results. In addition to the decrease in very low density lipopro-
tein (VLDL) cholesterol (253%) and triglyceride (246%) and
plasma apolipoprotein (apo) B (29%) levels, bezafibrate treat-
ment resulted in a significant increase in high density lipoprotein-3
(HDL3) cholesterol (19%) level and a shift in the low density
lipoprotein (LDL) subclass distribution toward larger particle
species (peak particle diameter 10.32 nm). The on-trial HDL3
cholesterol and plasma apo B concentrations were found to be
independent predictors of the changes in mean minimum lumen
diameter (r 5 20.23, p < 0.05), and percent (%) stenosis (r 5
0.30, p < 0.01), respectively. Decreases in small dense LDL and/or
VLDL lipid concentrations were unrelated to disease progression.
Conclusions. Our results suggest that the effect of bezafibrate
on progression of focal coronary atherosclerosis could be at least
partly attributed to a rise in HDL3 cholesterol and a decrease in
the total number of apo B-containing lipoproteins.
(J Am Coll Cardiol 1998;32:1648–56)
©1998 by the American College of Cardiology
Lipid-lowering therapy using 3-hydroxy-3-methylglutaryl-
coenzyme A (HMGCoA) reductase inhibitors resulting in a
substantial decrease in low density lipoprotein (LDL) choles-
terol concentration has been found to reduce the risk of
cardiovascular events in high risk individuals and patients with
manifest coronary artery disease (CAD) (1). Accordingly,
retardation of CAD progression in angiographic trials of
lipid-lowering therapy mainly affecting LDL has been accom-
panied by a beneficial effect on the risk of clinical events (2).
On-trial levels of LDL and high density lipoprotein (HDL)
cholesterol and of LDL and HDL subfractions have been
identified as determinants of lesion progression and regression
in most studies, the latter in a small subset of patients (3).
However, increasing evidence from angiographic studies shows
that triglyceride-rich lipoproteins are also important in pro-
gression of CAD (4–7). In particular, triglyceride-rich lipopro-
teins have a considerable impact in patients with mild-to-
moderate atherosclerotic lesions—that is, those causing less
than 50% stenosis (5,8).
A significant proportion of patients with precocious CAD
have hypertriglyceridemic lipoprotein phenotypes (9). Until
recently, no controlled coronary angiographic trial had focused
on the effects of intervention directed primarily toward lower-
ing of triglyceride-rich lipoproteins. The Bezafibrate Coronary
Atherosclerosis Intervention Trial (BECAIT) was the first
double-blind, placebo-controlled, randomized serial angio-
graphic trial of a fibrate compound (10). The BECAIT study
showed that progression of focal coronary atherosclerosis in
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young survivors of myocardial infarction could be retarded by
bezafibrate treatment and indicated that the treatment effect
on the primary study end point (change in mean minimum
lumen diameter [MLD]) was similar to the one obtained with
statins in the Multicentre Anti-Atheroma Study (MAAS) (11)
and the Regression Growth Evaluation Statin Study
(REGRESS) (12). The angiographic effects observed in the
bezafibrate-treated patients were accompanied by significant
reductions in very low density lipoprotein (VLDL) cholesterol
(235%) and triglycerides (231%) and an increase in HDL
cholesterol (19%), whereas LDL cholesterol concentrations
did not change.
In the present report from BECAIT, treatment effects on
lipids, lipoproteins, lipoprotein subfractions and apolipopro-
teins are presented in detail, and on-trial serum levels are
related to the angiographic outcome measurements. It was
hypothesized that the concentrations of triglyceride-rich li-
poproteins and/or HDL, along with that of LDL cholesterol,
would predict the progression of coronary lesions in the course
of the study.
Methods
Trial design. The rationale, design features and recruit-
ment procedures of the study have been reported (10,13). In
brief, all male survivors of a first myocardial infarction under
45 years of age, from the 10 hospitals with a coronary care unit
in Stockholm County, were considered for inclusion. The lipid
inclusion criteria, after a 3-month period of dietary interven-
tion, were cholesterol and triglyceride of at least 5.2 mmol/liter
and 1.6 mmol/liter, respectively. A total of 92 patients with
visually detectable lesions producing up to 90% luminal ob-
struction in at least one coronary segment were then randomly
assigned (by a block design) to double-blind treatment with
bezafibrate (200 mg three times daily) or placebo (47 bezafi-
brate, 45 placebo), having given informed consent to partici-
pate.
Blood sampling was performed every 4 months for deter-
minations of serum cholesterol, triglycerides and HDL choles-
terol. Cholesterol and triglyceride concentrations in VLDL
and LDL and serum apolipoprotein (apo) A-I, B and E levels
were measured on samples taken once a year. The LDL
particle size distribution was determined on serum samples
that had been drawn at baseline and 2 and 5 years after
randomization. Selective coronary angiography was repeated
after 2 and 5 years.
Lipid, lipoprotein and apolipoprotein analyses. The major
serum lipoproteins—that is, VLDL, LDL and HDL—were
determined by a combination of preparative ultracentrifuga-
tion and precipitation of apo B-containing lipoproteins, fol-
lowed by lipid analyses (14). Cholesterol (15) and triglycerides
(16) were quantified after chloroform-methanol extraction
(17) of whole serum, the VLDL fraction, the infranatant after
ultracentrifugation (containing LDL and HDL), and the su-
pernatant (HDL) after precipitation. The HDL3 was obtained
as a bottom fraction in which cholesterol was determined after
one preparative ultracentrifugal spin at a density of 1.125 kg/l
(18). Total HDL was obtained as described above. Next, HDL2
cholesterol was then calculated as the difference between total
HDL and HDL3 cholesterol. Serum lipoprotein (a) [Lp(a)]
was measured by an enzyme immunoassay (Tint Elize Lp(a),
Biopool). The assay utilizes affinity-purified polyclonal anti-
bodies raised against purified Lp(a) (19). Serum apos A-I and
B were determined by commercially available radioimmuno-
assays, and apo E by enzyme immunoassay (20).
LDL particle size distribution. Serum samples containing
1 mg of LDL cholesterol were applied to a 3% to 7.5%
polyacrylamide gradient gel. They had been kept frozen at
270°C and were applied immediately after thawing at room
temperature. All three samples from an individual patient
(taken at baseline and 2 and 5 years after randomization) were
applied to the same gel. Three standard reference proteins
were also applied to each gel (21). Electrophoresis was run
using Tris 90 mmol/liter, boric acid 80 mmol/liter and
Na2EDTA 3 mmol/liter, pH 8.35, as running buffer (22). A
double staining was performed. First a lipid staining was made
with Sudan Black 0.5% and zinc acetate 2.4% for 2 h at 37°C,
followed by destaining with 30% isopropanol; then, a protein
staining was made with 0.04% Coomassie Brilliant Blue G-250
(Serva, Heidelberg, Germany) and 3.5% perchloric acid for
15 min, followed by destaining with 7% acetic acid. The gels
were scanned twice (after the protein and lipid staining,
respectively) by a laser densitometer (Ultroscan XL,
Pharmacia-LKB) linked to a personal computer, and the area
under the curve was calculated automatically with the use of
the GelScan XL software package (Pharmacia-LKB). A linear
regression was made for each gel between the location of the
three reference proteins on the gel and their respective sizes.
Based on the regression line and the linear profile of the gel,
migration distance in the gel could be converted into LDL
particle diameter size. Because the size of the gels did not
change between the two stainings, the migration of reference
proteins was used for determining LDL peak particle size and
percent (%) small LDL from the densitometric scans of the
lipid-stained gels. The LDL particles with a diameter less than
22.8 nm were defined as small LDL. The coefficients of
variation for LDL peak particle size and for percentage small
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LDL were: intraassay 1.3% and 2.7%, interassay 2.3% and
6.6%, respectively.
Coronary angiography. Coronary angiographies were done
by the percutaneous transfemoral technique and recorded on
35-mm cine film with the aid of cesium-iodode-activated image
intensifiers, as described (10,23,24). The minimum lumen
diameter (MLD, which reflects focal atherosclerosis) was
measured at the site of the most severe atherosclerotic lesion
in each segment that reduced the lumen diameter by at least
20%. Mean segment diameter (MSD) was calculated in all
coronary segments irrespective of the presence of visually
detectable atherosclerosis, as an indicator of diffuse as well as
focal atherosclerosis. Percentage diameter stenosis (% steno-
sis) was calculated from the most narrow lesion in each
segment with a diameter reduction of at least 20%.
Statistical analysis. Continuous variables are presented as
mean 6 SD or median and interquartile range if not normally
distributed; categorical variables are presented as numbers and
percentages. The individual values of skewed variables were
transformed to their natural logarithms before statistical tests.
Per-patient means of MLD, MSD and % stenosis were calcu-
lated for baseline and repeat angiograms. The angiographic
outcome variables were median change (D) between the
baseline and the last follow-up angiogram for MLD and MSD,
and between the last follow-up and the baseline angiogram for
% stenosis. Only corresponding segments from the baseline
and follow-up angiograms were used in the assessment of
angiographic change. Student’s unpaired t test was used for
comparing baseline characteristics between the two treatment
groups. The responses of lipoprotein-related variables to the
study drug over time in the bezafibrate and placebo groups
were compared by two-way repeated measures analysis of
variance (ANOVA). The disease progression data (DMLD,
MSD and % stenosis) were used either as continuous variables
or divided according to tertiles. The association between
baseline clinical characteristics and tertiles of angiographic
outcome measurements was evaluated by ANOVA. The asso-
ciation between individual lipoprotein variables and disease
progression was first assessed by calculation of univariate
Pearson and partial correlation coefficients.
Treatment assignment and the baseline angiographic mea-
surements alone or treatment assignment, baseline angio-
graphic measurement, age, body mass index (BMI), smoking
and alcohol consumption were controlled for when calculating
partial correlation coefficients. Two multivariate models were
then generated by multiple stepwise linear regression analysis
to identify lipoprotein variables independently correlating with
the angiographic outcome variables. In the first model, treat-
ment assignment and the baseline angiographic measurement
were first entered as forced variables, whereas the second
model included treatment assignment, baseline angiographic
measurement, age, BMI, smoking and alcohol consumption as
forced variables. On-trial VLDL cholesterol, LDL cholesterol,
HDL2 cholesterol, HDL3 cholesterol, LDL triglycerides, apo
B, Lp(a), LDL peak particle size and % small LDL were
included in the model as independent variables. Backward
elimination of variables was used to establish the final model.
All statistical tests were two-sided and p values of less than 0.05
were considered significant.
Results
Baseline characteristics of the study groups. Baseline
characteristics of the 92 randomized patients have been de-
scribed in detail (10). The present report is based on the 81
patients (42 bezafibrate, 39 placebo) who had a baseline and at
least one posttreatment angiogram. The two study groups were
comparable in terms of baseline clinical and angiographic data.
The mean age was 41 years in each treatment group. Patients
with diabetes mellitus were not recruited to the study accord-
ing to the inclusion criteria. Hypertension was more prevalent
(p 5 0.06) among patients randomized to treatment with
bezafibrate (26%) than among those in the placebo group
(10%). The number of smokers was similar in the two study
groups (placebo 10, bezafibrate 12), as well as the average
alcohol consumption (placebo 415 g/week, bezafibrate 339
g/week, median values). Furthermore, the use of concomitant
medication was also comparable.
Treatment effects on lipids, lipoproteins and apolipopro-
teins. The treatment effect of bezafibrate on the serum levels
of lipids and some lipoproteins and apolipoproteins has been
published (10). Serum levels observed at baseline and at 1, 2,
3, 4 and 5 years after randomization are shown in Table 1. The
baseline levels were generally similar in the two study groups,
the exception being the slightly (p 5 0.08) higher Lp(a) level in
the placebo group. Over the 5-year follow-up, bezafibrate
treatment resulted in significant decreases (mean difference
between on-treatment mean and baseline serum concentra-
tions) of serum cholesterol (214%) and triglyceride (232%)
levels, whereas a smaller decrease of serum cholesterol (25%)
and an increase of serum triglycerides (18%) were observed in
the placebo group (p , 0.01 and p , 0.001 for group
differences in serum cholesterol and serum triglycerides, re-
spectively) (data not shown). The lowering of serum triglycer-
ide levels in the bezafibrate group was accounted for by the
significant lowering of triglycerides in the VLDL fraction
(246%), which was in contrast to the increase in VLDL
triglycerides (111%) in the placebo group (p , 0.001).
Conversely, a significant rise in LDL triglycerides was
observed in the bezafibrate group (16% vs. 21% in the
placebo group, p , 0.01). The lowering of serum cholesterol
levels in the bezafibrate group was also accounted for by a
significant lowering of cholesterol in the VLDL fraction
(253% vs. 27% in the placebo group, p , 0.001). No
significant differences were observed between the study groups
in on-trial LDL and HDL cholesterol levels. However, a 6%
increase in HDL cholesterol was observed in the bezafibrate
group compared to a 3% decrease in the placebo group. The
different responses of the two groups were mainly accounted
for by the HDL3 subfraction (9% increase in the bezafibrate;
4% decrease in the placebo group; p 5 0.02). In the placebo
group, HDL2 cholesterol levels tended to be higher at all time
1650 RUOTOLO ET AL. JACC Vol. 32, No. 6
LIPOPROTEINS AND CAD PROGRESSION November 15, 1998:1648–56
Table 1. Plasma, Lipid, Lipoprotein and Apolipoprotein Levels for Placebo and Bezafibrate Groups During the 5-Year Follow-up
Baseline 1 Year 2 years 3 years 4 Years 5 Years
p Value
Group Time Interaction
VLDL chol (mmol/liter) P 0.86 (0.60, 1.13) 0.81 (0.55, 1.06) 0.79 (0.54, 1.23) 0.77 (0.49, 1.18) 0.87 (0.47, 1.17) 0.76 (0.44, 1.06) , 0.0001 , 0.0001 0.005
B 1.10 (0.85, 1.61) 0.55 (0.38, 0.85)‡ 0.62 (0.37, 0.99)‡ 0.58 (0.35, 0.82)† 0.41 (0.30, 0.82)‡ 0.45 (0.29, 0.76)†
VLDL TG (mmol/liter) P 1.43 (1.12, 2.05) 1.42 (0.96, 2.11) 1.81 (0.98, 2.43) 1.45 (0.87, 2.24) 1.61 (0.89, 2.57) 1.65 (0.80, 2.42) , 0.0001 0.02 0.05
B 1.85 (1.09, 2.84) 0.97 (0.60, 1.39)‡ 1.06 (0.67, 1.70)‡ 0.94 (0.68, 1.62)† 0.93 (0.51, 1.75)‡ 1.07 (0.54, 1.63)†
LDL chol (mmol/liter) P 4.62 (3.80, 5.14) 4.65 (3.80, 5.12) 4.51 (3.90, 4.95) 4.38 (3.92, 4.90) 4.45 (3.85, 4.74) 4.41 (3.59, 4.85) 0.87 0.09 0.97
B 4.66 (3.89, 5.45) 4.41 (3.75, 5.14) 4.42 (3.53, 4.93) 4.65 (3.76, 5.10) 4.41 (3.63, 4.88) 4.11 (3.57, 4.94)
LDL TG (mmol/liter) P 0.41 (0.34, 0.51) 0.39 (0.33, 0.48) 0.42 (0.31, 0.51) 0.42 (0.36, 0.49) 0.40 (0.35, 0.47) 0.42 (0.37, 0.49) 0.005 0.34 0.96
B 0.42 (0.36, 0.53) 0.43 (0.33, 0.51) 0.44 (0.37, 0.53) 0.44 (0.36, 0.53) 0.43 (0.37, 0.52) 0.48 (0.37, 0.56)
HDL chol (mmol/liter) P 1.06 (0.95, 1.29) 1.14 (0.97, 1.29) 1.10 (0.86, 1.26) 1.07 (0.91, 1.28) 1.09 (0.84, 1.20) 0.98 (0.87, 1.17) 0.72 0.04 0.71
B 0.99 (0.87, 1.17) 1.09 (0.98, 1.30)† 1.04 (0.93, 1.30) 1.09 (0.95, 1.28) 1.00 (0.86, 1.29) 1.00 (0.84, 1.22)
HDL2 chol (mmol/liter) P 0.42 (0.30, 0.52) 0.45 (0.32, 0.57) 0.42 (0.30, 0.56) 0.41 (0.32, 0.58) 0.39 (0.22, 0.49) 0.28 (0.16, 0.38) 0.02 0.0004 0.79
B 0.34 (0.25, 0.47) 0.41 (0.29, 0.50) 0.35 (0.29, 0.49) 0.35 (0.26, 0.48) 0.38 (0.20, 0.48) 0.25 (0.13, 0.45)
HDL3 chol (mmol/liter) P 0.68 (0.60, 0.83) 0.69 (0.60, 0.78) 0.68 (0.57, 0.75) 0.67 (0.58, 0.74) 0.66 (0.57, 0.78) 0.69 (0.60, 0.77) 0.02 0.90 0.17
B 0.65 (0.59, 0.75) 0.71 (0.65, 0.78)† 0.69 (0.57, 0.81) 0.73 (0.63, 0.82)† 0.72 (0.60, 0.84) 0.74 (0.60, 0.84)*
Apo A-I (mg/l) P 1089 (951, 1176) 1063 (954, 1232) 1095 (949, 1205) 1073 (919, 1256) 1109 (969, 1244) 1077 (924, 1340) 0.46 0.62 0.82
B 1003 (932, 1143) 1100 (930, 1323)† 1074 (912, 1309) 1143 (996, 1244) 1118 (968, 1319) 1111 (1028, 1272)
Apo B (mg/l) P 1410 (1216, 1542) 1429 (1264, 1661) 1374 (1285, 1511) 1387 (1254, 1539) 1399 (1282, 1619) 1431 (1258, 1561) 0.05 0.52 0.26
B 1424 (1191, 1765) 1300 (1075, 1585)† 1309 (1095, 1515) 1336 (1126, 1620) 1336 (1058, 1494)* 1386 (1091, 1535)
Apo E (mg/l) P 53 (43, 62) 52 (44, 63) 52 (44, 64) 50 (44, 60) 52 (48, 64) 49 (43, 60) 0.0005 0.48 0.55
B 52 (46, 62) 49 (42, 58) 47 (38, 55)* 51 (44, 56) 48 (40, 56)* 46 (39, 58)
Lp(a) (mg/l) P 230 (117, 560) 226 (68, 582) 210 (95, 451) 220 (102, 561) 196 (87, 515) 195 (79, 526) 0.0005 0.99 0.99
B 133 (59, 428) 123 (51, 412) 117 (50, 379) 134 (52, 406) 166 (54, 387) 124 (47, 376)
Values are median and interquartile range. P indicates placebo; B, bezafibrate; Chol, cholesterol; TG, triglycerides; apo, apolipoprotein; and Lp(a), lipoprotein(a). Data were analyzed by two-way repeated measures
analysis of variance followed by post hoc comparisons. *p , 0.05; †p , 0.01; ‡p , 0.001 vs. placebo group.
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points. The Apo B and apo E levels were significantly lowered
(29% for both) by bezafibrate treatment, whereas a slight
increase (11%) was observed for both apolipoprotein levels in
the placebo group (p 5 0.05 and p , 0.001 for group
differences in apo B and apo E, respectively). Like HDL
cholesterol, on-treatment apo A-I did not differ between the
study groups, even though a 10% increase was observed in the
bezafibrate compared to a 1% decrease in the placebo group.
The Lp(a) levels were higher in the placebo group at all time
points and seemed to be unaffected by bezafibrate treatment.
LDL gradient gel electrophoresis. Table 2 shows baseline,
on-trial and D values for LDL peak particle size and % small
LDL in the two study groups. The LDL peak particle size and
% small LDL were measured at baseline and at 2 and 5 years.
On-trial values represent the means of the 2- and 5-year
measurements; D values are differences between on-treatment
means and baseline values. Bezafibrate treatment resulted in
significant changes in both LDL peak particle size (10.32 nm
vs. 10.02 nm in the placebo group, p 5 0.0008) and % small
LDL (29.7% vs. 20.3% in the placebo group, p 5 0.0002).
Thus, LDL peak particle size increased, while % small LDL
decreased by bezafibrate treatment in young male postinfarc-
tion patients. The treatment effects persisted unattenuated
after 5 years (Fig. 1).
Relationships to angiographic outcome measurements.
Tables 3 and 4 summarize the relationships of clinical findings
and plasma lipoproteins to the progression of coronary lesions
during the trial. The DMSD is excluded from the presentation,
as this angiographic variable proved to be unrelated to all
lipoprotein measurements. Table 3 shows baseline clinical
characteristics according to tertiles of the angiographic out-
come measurements. The low tertile group comprises patients
who progressed least, the high tertile group those who pro-
gressed most. The BMI was related to change in % stenosis
(D% stenosis), that is, patients who progressed less had lower
BMI, whereas those who progressed more had higher BMI.
The BMI also showed a borderline association with change in
MLD (DMLD). Also, the baseline MLD was directly related to
changes in both MLD and % stenosis. In contrast, baseline %
stenosis was inversely related to changes in both MLD and %
stenosis; that is, patients with higher values for baseline %
stenosis progressed less, while those with lower % stenosis
values progressed more.
Table 4 shows univariate Pearson and partial correlation
coefficients among on-trial lipid, lipoprotein and apo measure-
ments and angiographic outcome variables, the latter when we
controlled for treatment assignment and baseline angiographic
score, age, BMI, smoking and alcohol consumption. In accor-
dance with the analyses according to tertiles of the angio-
graphic outcome measurements (Table 3), BMI and baseline
angiographic status correlated significantly with both DMLD
and D% stenosis. On-trial HDL3 cholesterol levels were in-
versely related to DMLD (r 5 20.23, p , 0.05), whereas total
apo B level was directly related to D% stenosis (r 5 0.30, p ,
0.01). The inverse HDL3 cholesterol relation to DMLD re-
mained significant after control for treatment assignment and
the baseline angiographic measurement (r 5 20.22, p , 0.05)
as did the positive apo B correlation with D% stenosis (r 5
Figure 1. LDL peak particle size (upper panel) and percentage small
LDL (,22.8 nm) of total LDL (lower panel) in the two study groups
(circles, placebo; squares, bezafibrate). LDL peak particle size and
percentage small LDL were measured at baseline and at 2 and 5 years.
Values are mean 6 SD. Data were analyzed by two-way repeated
measures ANOVA (LDL peak particle size: group p 5 0.27, time p 5
0.0003, interaction p 5 0.001; percentage small LDL: group p 5 0.76,
time p , 0.0001, interaction p , 0.0001). *p , 0.05, ***p , 0.001
between D values of the two study groups.
Table 2. Baseline, On-Trial and D Values of LDL Peak Particle Size
and Percentage Small LDL of Total LDL in the Two Study Groups
Placebo Bezafibrate p Value
LDL peak particle size (nm)
Baseline 23.1 6 0.5 23.0 6 0.5 0.45
On-trial 23.1 6 0.4 23.3 6 0.5 0.05
D 0.02 6 0.32 0.32 6 0.43 0.0008
% Small LDL
Baseline 35.9 6 13.9 41.4 6 14.4 0.08
On-trial 35.4 6 12.6 30.8 6 15.9 0.17
D 20.3 6 10.7 29.7 6 10.4 0.0002
Values are mean 6 SD. On-trial values are the means of 2- and 5-year
values; D indicates the difference between on-trial and baseline values. Data were
analyzed by unpaired Student’s t test.
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0.34, p , 0.01). In addition, control for treatment assignment
and baseline angiographic status rendered the positive LDL
cholesterol correlation with D% stenosis statistically significant
(r 5 0.22, p , 0.05).
Although the inverse relationship between on-trial HDL3
cholesterol concentration and DMLD weakened slightly when
also BMI, smoking and alcohol consumption were included as
covariates (r 5 20.18, NS), the on-trial apo B and LDL
Table 3. Baseline Clinical Characteristics According to Tertiles of Angiographic Outcome Measurements
DMLD D% Stenosis
Low Medium High p Value Low Medium High p Value
Age (years) P 43 (36, 44) 43 (39, 44) 42 (37, 43) NS 43 (39, 45) 43 (37, 44) 40 (37, 43) NS
B 42 (41, 43) 41 (38, 42) 42 (41, 44) 41 (41, 43) 41 (40, 42) 42 (40, 44)
BMI (kg/m2) P 25.6 (24.4, 27.0) 25.5 (22.1, 29.5) 28.0 (24.4, 30.6) 0.09 25.4 (22.9, 27.0) 26.6 (24.5, 29.5) 25.5 (24.8, 31.9) 0.04
B 25.7 (23.1, 29.1) 26.5 (25.1, 29.2) 29.6 (26.5, 32.2) 25.3 (23.1, 26.8) 28.9 (26.5, 30.9) 28.2 (24.9, 31.4)
Smoking (g/day) P 20 (0, 27) 10 (0, 20) 10 (0, 30) NS 20 (0, 30) 18 (0, 25) 10 (0, 22) NS
B 21 (15, 30) 30 (19, 40) 20 (0, 34) 20 (13, 30) 25 (20, 32) 20 (0, 35)
Alcohol (g/week) P 400 (256, 955) 206 (100, 569) 320 (67, 492) NS 392 (253, 884) 365 (206, 787) 250 (37, 477) NS
B 337 (120, 505) 345 (230, 468) 205 (64, 280) 337 (168, 505) 300 (199, 413) 253 (95, 413)
Hypertension n (%) P 1 (8) 1 (8) 2 (15) NS 1 (8) 1 (8) 2 (15) NS
B 4 (29) 5 (36) 2 (14) 2 (14) 7 (50) 2 (14)
Baseline
MLD (mm) P 1.40 (1.31, 1.74) 1.91 (1.70, 2.10) 2.06 (1.94, 2.31) , 0.0001 1.40 (1.30, 1.84) 1.91 (1.78, 2.13) 1.98 (1.79, 2.21) 0.006
B 1.62 (1.47, 2.17) 1.77 (1.50, 1.92) 1.86 (1.70, 2.10) 1.62 (1.47, 2.13) 1.90 (1.62, 1.99) 1.83 (1.57, 2.06)
Stenosis (%) P 40.8 (34.4, 48.5) 35.3 (30.0, 38.2) 27.6 (24.6, 34.3) 0.0007 40.8 (37.0, 46.1) 33.3 (27.9, 36.5) 29.1 (25.7, 36.8) 0.002
B 36.5 (32.5, 46.2) 36.4 (28.4, 45.4) 36.0 (28.7, 41.0) 37.8 (31.9, 46.2) 36.4 (30.8, 43.8) 34.7 (26.9, 39.6)
Values are median and interquartile range. P indicates placebo; B, bezafibrate; BMI, body-mass index; MLD, minimum lumen diameter; D, median change between
the baseline and the last follow-up angiogram for MLD, and between the last follow-up and the baseline angiogram for % stenosis; NS, not statistically significant. The
low tertile group comprises patients who progressed least; the high tertile group comprises those who progressed most. Data were analyzed by analysis of variance. The
p value refers to variance analysis of both groups combined.
Table 4. Univariate and Multiple Stepwise Regression Analyses of the Relations of Baseline Characteristics and On-Trial Lipid, Lipoprotein
and Apolipoprotein Concentrations to the Angiographic Outcome Measures
DMLD D% Stenosis
Pearson
correlation
coefficients
Partial correlation
coefficients
Final model:
Increase in R2 Pearson
correlation
coefficients
Partial correlation
coefficients
Final model:
Increase in R2
Model 1§ Model 2¶ Model 1§,# Model 2¶,# Model 1§ Model 2¶ Model 1§,# Model 2¶,#
Age 20.07 20.14 . . . 0.02 20.19 20.22* . . . 0.06
BMI 0.26* 0.22* . . . 0.04 0.23* 0.27* . . . 0.04
Smoking 20.15 20.02 . . . 0.01 20.18 20.14 . . . 0.01
Alcohol 20.18 20.14 . . . 0.01 20.16 20.14 . . . 0.01
Baseline MLD 0.53‡ . . . . . . 0.25 0.26 0.39‡ 0.19 0.17 0.03 0.03
Baseline %
stenosis
20.42‡ 20.07 20.09 . . . . . . 20.38‡ . . . . . . 0.15 0.13
VLDL chol 0.03 20.03 20.13 . . . . . . 0.09 0.10 0.01 . . . . . .
LDL chol 20.03 0.03 20.02 . . . . . . 0.15 0.22* 0.21 . . . . . .
HDL2 chol 20.10 20.18 20.13 . . . . . . 20.09 20.18 20.13 . . . . . .
HDL3 chol 20.23* 20.22* 20.18 0.03 . . . 20.14 20.19 20.14 . . . . . .
LDL TG 0.13 0.16 0.14 . . . . . . 0.12 0.11 0.26* . . . . . .
Apo B 0.18 0.13 0.03 . . . . . . 0.30† 0.34† 0.30† 0.07 0.05
Lp(a) 0.16 20.01 0.04 . . . . . . 0.11 0.03 0.06 . . . . . .
LDL peak
particle size
0.01 0.09 0.18 . . . . . . 0.02 0.06 0.12 . . . . . .
% Small LDL 0.03 20.06 20.11 . . . . . . 20.02 20.03 20.08 . . . . . .
Multiple R2 0.34 0.40 0.29 0.38
BMI indicates body-mass index; MLD, minimum lumen diameter; apo, apolipoprotein; chol, cholesterol; TG, triglycerides; D, median change between the baseline
and the last follow-up angiogram for MLD, and between the last follow-up and the baseline angiogram for % stenosis. §Treatment assignment and baseline
angiographic measurement or ¶treatment assignment, baseline angiographic measurement, age, BMI, smoking and alcohol consumption were controlled for when
calculating partial correlation coefficients or included as forced variables in the multiple stepwise regression analysis. The contribution of treatment assignment to the
multiple R2 was 0.06 for both DMLD and D% stenosis. #Variables included in the final multiple regression equation and their respective contribution to the value of
R2. *p , 0.05; †p , 0.01; ‡p , 0.001.
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cholesterol correlations with D% stenosis were only marginally
affected (r 5 0.30, p , 0.01, and r 5 0.21, NS, respectively). Of
note, the LDL triglyceride content was also directly related to
D% stenosis (r 5 0.26, p , 0.05) after control for the full range
of clinical confounders.
Percentage change in serum lipid, lipoprotein and apo
concentrations from baseline to mean on-trial levels did not
correlate significantly with any of the angiographic outcome
variables (partial correlation coefficients were computed with
control for treatment assignment, baseline angiographic score,
age, BMI, smoking and alcohol consumption).
Multiple stepwise regression analysis was used to study the
independent relations of on-trial lipid, lipoprotein and apo
measurements to the angiographic outcome measurements
(Table 4). Treatment assignment and baseline angiographic
score were entered as forced variables in the first model.
On-trial HDL3 cholesterol level was found to be independently
and inversely related to DMLD in this model, accounting for
3% of the multiple R2. Inclusion of other lipoprotein variables
did not significantly increase the value of R2. On-trial serum
apo B level was independently related to D% stenosis in the
first model, accounting for 7% of the multiple R2. On-trial
HDL3 cholesterol was not retained in the second multivariate
model where, in addition to treatment assignment and the
basic angiographic measurement, age, BMI, smoking and
alcohol consumption were entered as forced variables. In
contrast, serum apo B remained independently related to D%
stenosis also in the second multivariate model, accounting for
5% of the multiple R2. It is notable that baseline angiographic
status was by far the strongest determinant of change in
angiographic outcome variables.
The on-trial lipid, lipoprotein and apo relationships to
changes in coronary lesions, summarized in Table 4, did not
alter materially when we also controlled for the baseline
lipoprotein measurements.
Discussion
Bezafibrate treatment of young male postinfarction patients
with dyslipoproteinemia resulted in the expected decrease of
VLDL lipid concentrations (both cholesterol and triglycerides)
and plasma apo B, a shift in the LDL subclass distribution
toward larger particle species, increase of the HDL3 choles-
terol levels and changes in the lipoprotein profile that persisted
throughout the 5-year follow-up period. Furthermore, bezafi-
brate induced an increase in the LDL triglyceride concentra-
tion and appeared to counteract a decline in HDL2 cholesterol
concentration over time. The increase in HDL3 cholesterol
and the decrease in plasma apo B were accompanied by a
lesser progression of focal coronary atherosclerosis, as re-
flected by changes in mean MLD and % stenosis, respectively.
HDL effects. The BECAIT is the first controlled angio-
graphic study demonstrating that treatment with a fibrate
compound, bezafibrate, has beneficial effects on progression of
focal coronary atherosclerosis (10). This effect could thus at
least partly be attributed to a rise in HDL3 cholesterol
concentration. Several serial angiographic studies have previ-
ously demonstrated an inverse relationship between increase
in HDL, or its subfractions, and coronary artery disease
progression, using different lipid-lowering treatment modali-
ties. Increase of HDL2a and HDL2b subfractions (by cho-
lestyramine treatment) was first found to be associated with
slowing of progression or regression of CAD in the National
Heart, Lung and Blood Institute (NHLBI) Type II Coronary
Intervention Study (25). Subsequently, increase of HDL cho-
lesterol levels has been linked to retarded progression of
disease also in studies using colestipol and/or niacin (26,27),
lovastatin (27) and pravastatin (28). It has been suggested that
the HDL cholesterol-mediated effect of lipid-lowering treat-
ment is mainly confined to smaller lesions causing ,50%
diameter stenosis (29). Such lesions dominated in the BECAIT
cohort (78% of the lesions), and the bezafibrate effect on
disease progression was restricted to mild-to-moderate lesions
(30). The inverse association between on-trial HDL3 choles-
terol level and disease progression could be explained by the
active role of this lipoprotein species in reverse cholesterol
transport.
LDL and its particle size distribution. As expected (31),
bezafibrate treatment affected the LDL particle size distribu-
tion, reducing the small LDL particle subfraction and increas-
ing the LDL peak particle size. The probable mechanism
underlying the shift of LDL particles toward greater particle
size is inhibition of lecithin:cholesterol acyltransferase (LCAT)
and cholesteryl ester transfer protein (CETP) activities by
bezafibrate (31) as well as a reduction in acceptor lipoproteins
for the exchange of core lipid constituents. The decreased
production of esterified cholesterol in HDL, and its decreased
heteroexchange with triglyceride in larger and lighter LDL,
would explain both the increase in LDL triglycerides and the
concomitant increase in LDL peak particle size. The % dense
LDL was unrelated to progression of both focal and diffuse
coronary lesions. This is surprising as a small and dense LDL
particle distribution pattern has been firmly linked to CAD
(32). In contrast, the LDL triglyceride concentration, reflecting
intermediate density lipoprotein (IDL) and larger and
triglyceride-enriched LDL particles, was related to progression
of distinct stenoses when confounders like smoking, alcohol
consumption and BMI were taken into account. This is in
agreement with studies that have linked IDL to CAD progres-
sion (6,33).
Despite its retarding effect on the further progression of
focal coronary atherosclerosis, bezafibrate did not significantly
influence the LDL cholesterol levels of the young postinfarc-
tion patients. Furthermore, on-trial LDL cholesterol levels
were not related to change in mean MLD and only correlated
weakly with change in % stenosis. However, it is notable that
whole-serum apo B, primarily a marker of LDL particle
number (34), was the strongest predictor of progression of
distinct stenoses, as reflected by the % stenosis outcome
measurement. This is in accord with most previous angio-
graphic studies and suggests that the number of apo
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B-containing lipoproteins is an important determinant of the
progression of focal atherosclerotic lesions and that the de-
crease in the total number of atherogenic apo B-containing
particles seen in bezafibrate-treated patients in BECAIT con-
tributed to the beneficial effect on the further progression of
distinct stenoses.
Role of triglyceride-rich lipoproteins. Triglyceride-rich li-
poproteins are indicated to be particularly important for the
progression of coronary lesions causing (,50% diameter ste-
nosis (5,8), the predominant lesion size in the young postin-
farction patients participating in BECAIT (30). The main
triglyceride-rich lipoproteins involved in this process are
VLDL and their remnants, including IDL. The largest effect of
bezafibrate treatment observed in BECAIT was the lowering
of VLDL lipid concentrations. However, neither changes in
VLDL lipids nor on-trial VLDL lipid levels correlated with the
angiographic outcome measurements. This apparent discrep-
ancy is likely to be accounted for by the fact that lipid
concentrations in the total (density ,1.006 kg/l) VLDL frac-
tion mainly reflect the larger VLDL species, whereas primarily
the small (Sf 20–60) VLDL remnants and IDL have been
implicated in the progression of CAD (6,33).
Nonlipoprotein effects. Finally, the on-trial lipoprotein
concentrations and the changes in individual lipoprotein frac-
tions attributable to bezafibrate only explained part of the
disease progression in BECAIT. The remaining part of the
bezafibrate effect on CAD progression might have been due to
nonlipoprotein mediated effects of the compound. For in-
stance, bezafibrate has favorable effects on blood coagulation
and fibrinolysis, which may be at least partly mediated by
lowering of the plasma concentrations of triglyceride-rich
lipoproteins (35). Of note, the plasma fibrinogen concentra-
tion, an established risk factor for CAD, fell substantially in the
bezafibrate-treated group in BECAIT (treatment effect
212%) (10). However, the on-trial fibrinogen levels were not
related to the angiographic outcome measurements (data not
shown). Fibrates, which are gene regulators through activation
of the peroxisome proliferator-activated receptor (36), may
induce yet unknown protective mechanisms in the vascular
wall. Limitations of this study, including the relatively small
sample size and the fact that subfractions of triglyceride-rich
lipoproteins were not determined directly, also restrict the
interpretations of the current data. In particular, IDL was
included in the LDL fraction.
Summary and implications. In conclusion, BECAIT is the
first controlled angiographic study demonstrating that treat-
ment with a fibrate compound, bezafibrate, has beneficial
effects on the progression of focal coronary atherosclerosis.
This effect could at least partly be attributed to a bezafibrate-
induced rise in HDL3 cholesterol concentration, and a de-
crease in whole serum apo B, a marker of LDL particle
number, which proved to be a strong predictor of progression
of distinct stenoses. Furthermore, support was obtained for the
notion that IDL is implicated in progression of CAD. Analysis
of the lipoprotein relations to the angiographic outcome
suggests that bezafibrate also exerts beneficial nonlipoprotein-
mediated effects in patients with manifest CAD. In all,
BECAIT provides further evidence that LDL and its choles-
terol content are not the sole determinants of CAD progres-
sion and shows that bezafibrate treatment, mainly affecting
triglyceride-rich lipoproteins and HDL, retards the further
development of coronary lesions in patients with precocious
CAD.
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